Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Rhea-AI Summary
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has scheduled its second quarter 2025 earnings conference call for August 7, 2025, at 8:00 a.m. ET. The company will discuss financial results and operational highlights during the call.
Investors can access the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will be available, and a replay will be accessible through Intellia's website after 12 p.m. ET on the same day.
Positive
- None.
Negative
- None.
News Market Reaction – NTLA
On the day this news was published, NTLA declined 5.60%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 7, 2025, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
When is Intellia Therapeutics (NTLA) Q2 2025 earnings call?
How can investors join Intellia Therapeutics' Q2 2025 earnings call?
Where can I find the replay of Intellia Therapeutics' Q2 2025 earnings call?
What will Intellia Therapeutics discuss in their Q2 2025 earnings call?
